Related Experiment Video
Updated: Jun 14, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Exploring a Novel Role of Glycerol Kinase 1 in Prostate Cancer PC-3 Cells
Bobae Park1,2, Sang-Hun Kim3, Sun-Nyoung Yu2
1Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Abstract:
Clinically, prostate cancer is infamous for its histological and molecular heterogeneity, which causes great challenges to pinpoint therapy and pharmaceutical development. To overcome these difficulties, researchers are focusing on modulating tumor microenvironment and immune responses in addition to genetic alteration and epigenetic regulation. Here, we aimed to identify potential biomarkers or modulators of prostate cancer by investigating genes specifically altered in prostate cancer cells treated with established anti-cancer agents. Glycerol kinase 1 (GK1) is phosphotransferase encoded on the X chromosome, is associated with the synthesis of triglycerides and glycerophospholipids, and has been mainly studied for X-linked metabolic disorder GK deficiency (GKD). Interestingly, our DNA microarray analysis showed that several anti-cancer agents highly induced the expression of GK1, especially GK1a and GK1b isoforms, in human prostate cancer PC-3 cells. To elucidate the relationship between GK1 and cancer cell death, a human GK1b-specific expression vector was constructed and transfected into the PC-3 cells. Surprisingly, GK1b overexpression dramatically reduced cell viability and significantly accelerated apoptotic cell death. These findings suggest that GK1b may serve as a promising modulator and biomarker of cell death in prostate cancer, offering potential avenues for therapeutic intervention.
Insights
Glycerol kinase 1 (GK1) gene expression, particularly GK1b, was significantly induced by anti-cancer agents in prostate cancer cells. Overexpression of GK1b accelerated cell death, suggesting its potential as a prostate cancer biomarker and therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Prostate cancer exhibits significant heterogeneity, complicating targeted therapies.
- Modulating the tumor microenvironment and immune responses are key research areas.
- Identifying novel biomarkers and therapeutic targets is crucial for effective prostate cancer treatment.
Purpose of the Study:
- To identify genes altered in prostate cancer cells treated with anti-cancer agents.
- To investigate the role of Glycerol kinase 1 (GK1) in prostate cancer cell death.
- To evaluate GK1b as a potential biomarker or therapeutic modulator for prostate cancer.
Main Methods:
- DNA microarray analysis of human prostate cancer PC-3 cells treated with anti-cancer agents.
- Construction and transfection of a human GK1b-specific expression vector into PC-3 cells.
- Assessment of cell viability and apoptotic cell death following GK1b overexpression.
Main Results:
- Several anti-cancer agents significantly induced the expression of GK1, specifically GK1a and GK1b isoforms, in PC-3 cells.
- Overexpression of GK1b in PC-3 cells led to a dramatic reduction in cell viability.
- GK1b overexpression significantly accelerated apoptotic cell death in prostate cancer cells.
Conclusions:
- GK1b shows promise as a modulator of cell death in prostate cancer.
- GK1b may serve as a valuable biomarker for prostate cancer.
- Targeting GK1b could offer new therapeutic strategies for prostate cancer intervention.
More Related Videos
08:43Identification, Histological Characterization, and Dissection of Mouse Prostate Lobes for In Vitro 3D Spheroid Culture Models
Published on: September 18, 2018
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
GPCRs Regulate Adenylyl Cylase Activity
cAMP-dependent Protein Kinase Pathways
IP3/DAG Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...